On-demand BERINERT helps you BE prepared for HAE attacks
BERINERT is a fast-acting, on-demand treatment for attacks of swelling caused by hereditary angioedema (HAE)
- BERINERT works at the root cause of HAE attacks by adding functioning C1-INH to your body, a key protein that is either missing or non-functioning in people with HAE.
- With training, you can self-administer BERINERT, so you can get relief when and where you need it.
“Without BERINERT, my abdomen attacks would last for days. I would miss school and spend a lot of hours in pain.”
–BERINERT patient
Photo does not depict
actual patient.
Photo does not depict actual patient.
At the first sign of an HAE attack, you want an on-demand treatment that works fast and keeps on working until your symptoms are resolved.
Laryngeal attacks
In a clinical trial, the time to onset of symptom relief was 15 minutes.*
The time to complete resolution of symptoms was 8.4 hours.*
In a clinical trial, the time to onset of symptom relief was 15 minutes.*
The time to complete resolution of symptoms was 8.4 hours.*
Abdominal and facial attacks
In a clinical trial, the time to onset of symptom relief was 48 minutes.*
The time to complete resolution of symptoms was under 5 hours.*
In a clinical trial, the time to onset of symptom relief was 48 minutes.*
The time to complete resolution of symptoms was under 5 hours.*
*Median time.
BERINERT addresses HAE at the root cause by adding functioning C1-INH to your body
HAE attacks are caused by low levels of functioning C1-INH, a key protein in your body that controls swelling. BERINERT adds functioning C1-INH to your body, rapidly halting the progress of an HAE attack and providing fast onset of relief.
Weight-based dosing
Your BERINERT dose is calculated by weight. That means you get an individualized amount of medicine—for your body.
On demand therapy
And because BERINERT is given on demand for acute attacks, you take it only when you need it.
- The most serious adverse reaction reported in subjects who received BERINERT in clinical studies was an increase in the severity of pain associated with HAE.
- Dysgeusia, a bad taste in the mouth, was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.
Want to learn more about HAE?
Get information about HAE, symptoms of an attack, warning signs and triggers, and more.
Get more information